Patents by Inventor Robert Alan Singer

Robert Alan Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation Of A Pyrimidinyl-3,8-Diazabicyclo[3.2.1]Octanylmethanone Derivative And Salt Thereof
    Publication number: 20230265101
    Abstract: Methods for preparing ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]-octan-8-yl)methanone and intermediates used in the processes of preparation thereof.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 24, 2023
    Applicant: PFIZER INC.
    Inventors: Adam Edward GOETZ, Sally Gut RUGGERI, Robert Alan SINGER
  • Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
    Patent number: 9475793
    Abstract: The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: October 25, 2016
    Assignee: Pfizer Inc.
    Inventors: Janice Ethel Sieser, Robert Alan Singer
  • CONJUGATES AND ASSOCIATED METHODS OF PRODUCING THEM FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION
    Publication number: 20160176846
    Abstract: The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Inventors: Janice Ethel Sieser, Robert Alan Singer
  • Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
    Patent number: 9303013
    Abstract: The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: April 5, 2016
    Assignee: Pfizer Inc.
    Inventors: Janice Ethel Sieser, Robert Alan Singer
  • CONJUGATES AND ASSOCIATED METHODS OF PRODUCING THEM FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION
    Publication number: 20150329520
    Abstract: The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.
    Type: Application
    Filed: May 1, 2015
    Publication date: November 19, 2015
    Inventors: Janice Ethel Sieser, Robert Alan Singer
  • Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
    Patent number: 8791140
    Abstract: The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: July 29, 2014
    Assignee: Pfizer Inc.
    Inventors: Anthony Michael Campeta, Brian Patrick Chekal, Robert Alan Singer
  • CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS
    Publication number: 20100179329
    Abstract: The present invention relates to crystalline polymorphic and amorphous form of 6-[2-(methylcarbamoyl)phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one polymorphic form and to the therapeutic or prophylactic use of such polymorphic forms and compositions.
    Type: Application
    Filed: March 25, 2008
    Publication date: July 15, 2010
    Inventors: Anthony Michael Campeta, Brian Patrick Chekal, Robert William McLaughlin, Robert Alan Singer